In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Biogen pays Forward Pharma non-refundable $1.25bn for IP rights

Executive Summary

Under terms of a binding agreement, Biogen Inc. is paying $1.25bn in exchange for an irrevocable license to all intellectual property owned by Forward Pharma AS in the US. The license term is perpetual and exclusive but subject to certain conditions which, if not satisfied, can change to co-exclusive in which case Biogen would pay a 1% royalty starting January 1, 2023 until the earlier of the expiration, unenforceability, or invalidation of the patents in the US.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register